Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
about
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic reviewTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusDietary interventions to extend life span and health span based on calorie restrictionPlace of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statementCardiovascular importance of hyperglycemia and hypoglycemiaCellular and molecular mechanisms of metformin: an overviewImpact of hypoglycemic agents on myocardial ischemic preconditioningGlycemic control and cardiovascular disease: what's a doctor to do?Compliance with clinical practice guidelines for type 2 diabetes in rural patients: treatment gaps and opportunities for improvementIdentification of major cardiovascular events in patients with diabetes using primary care data.A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus.Optimal therapy of type 2 diabetes: a controversial challengeValidation of anti-aging drugs by treating age-related diseases.Metformin increases plasma ghrelin in Type 2 diabetes.The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysisRandomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.Patient factors associated with hemoglobin A1C change with pioglitazone as adjunctive therapy in type 2 Diabetes Mellitus.Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort studyDose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort studyMetformin mitigates apoptosis in ischemic myocardiumIncreased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort studyMetformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium.Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.Frailty Attenuates the Impact of Metformin on Reducing Mortality in Older Adults with Type 2 DiabetesMetformin use in patients with type 2 diabetes mellitus is associated with reduced risk of deep vein thrombosis: a non-randomized, pair-matched cohort study.Analyzing composite outcomes in cardiovascular studies: traditional Cox proportional hazards versus quality-of-life-adjusted survival approaches.Time to be cautious about prescribing sulfonylureas?Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression.Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes.Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease.Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?AMP-activated protein kinase regulates E3 ligases in rodent heart.Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular eventsReduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.Insulin resistance in patients with polycystic ovary syndrome.The insulin receptor: a new target for cancer therapy.Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?Glycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum.Association of APOE polymorphisms with diabetes and cardiometabolic risk factors and the role of APOE genotypes in response to anti-diabetic therapy: results from the AIDHS/SDS on a South Asian population.
P2860
Q22242077-1E27CBFE-E232-4A7A-8ABF-FC7694A76BD2Q24241529-64A48436-4777-41AE-9D14-4A055D98A5F6Q24595003-2F5985E9-7BA8-4172-983A-4E0B58C9BAA9Q26783199-ED9BFE2F-6566-4B34-A092-05F8193795A7Q26999390-67F041AE-1440-426E-B156-FB6D79E4EC0CQ27013561-14993893-F1F3-42A3-AACE-E1586A9E82C6Q27014018-468885BB-C434-4DA7-8477-92FA6A7085D4Q27024469-1D113FFD-6A2A-47B9-80D1-408502FA6D9BQ28195948-C5FC10FF-8012-4D1C-BAA2-6EC6C6901FAFQ31067093-4C3C26A4-1C6C-4BA2-B715-F78BE4CB6B83Q33561396-6CCD3511-AF9F-4315-8A4E-47B73CB7844DQ33577712-8C633B5C-CBDC-4FCF-8D47-3D5305E8E475Q33588700-CD3D53D5-7CA3-4340-B09D-EE376771B6CCQ33607992-5012875E-B73F-48B1-853C-9406C1587112Q33873053-9BF62E35-9593-4114-99C3-01A6418A23B8Q33880174-D81BD423-9623-400B-98E2-583CE629BC97Q33932712-35D641C0-FCA3-44CF-8787-5CAFD82E7991Q34078900-2F2C584E-7F1A-4CD6-B036-2CF043CB316BQ34158078-83C1AEC7-9F13-46F5-BEC3-AFECBB97E55AQ34257350-126DE33C-9995-44B4-BB66-F5E5A4DD4507Q34302365-6C994CA6-ED88-4625-BB44-5FC424C3E4DEQ34495632-C152F719-9789-4665-B8B5-5A6F4E4CB0C6Q34505650-043D3F15-C6B7-49FB-A923-6099D65715EDQ34592900-07AAA7D4-A05E-41FD-B526-C516F567FC30Q34684420-BB9F578C-98EF-4E23-9730-B8AA2BD7B560Q34762025-B5AF2194-754D-4217-8178-3E74957ADBAFQ35049849-A29DC23D-CA3A-4E29-9A7C-FD236C5D99AFQ35076020-3EBC30C4-715A-4A41-A180-2FC934DBDCDEQ35118914-2C898E79-38EF-4125-8A1D-0AC2B7855596Q35183780-9483B324-618F-42BA-A081-0069744D1410Q35588998-172709D1-639B-42DE-B7F3-7C747955C5AFQ35607945-FF64C264-C82C-410F-91C9-F5CB65E83C97Q35661532-68A48DE1-6E32-4CC1-A089-37BB4DF1188BQ35736564-3BF2B717-BC50-4A45-B49C-CB623AC8A76EQ35847886-A847FF57-A251-44E9-9DC6-51C79CD1A016Q35932352-A0473530-C0A9-48BD-924C-59615E926FBBQ35972002-52CB1E48-7FBC-4140-B3F1-C0BC63A730E0Q35981002-FEB84CE4-E051-4068-92C7-C8E2206A7BF1Q36194911-63FB7440-4BB6-44CD-9B77-528C6609F494Q36307711-C7D0F147-8B64-4E0D-9884-FCA0FA8DDB9C
P2860
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Decreased mortality associated ...... onotherapy in type 2 diabetes.
@en
Decreased mortality associated ...... onotherapy in type 2 diabetes.
@nl
type
label
Decreased mortality associated ...... onotherapy in type 2 diabetes.
@en
Decreased mortality associated ...... onotherapy in type 2 diabetes.
@nl
prefLabel
Decreased mortality associated ...... onotherapy in type 2 diabetes.
@en
Decreased mortality associated ...... onotherapy in type 2 diabetes.
@nl
P2093
P1433
P1476
Decreased mortality associated ...... onotherapy in type 2 diabetes.
@en
P2093
Ellen L Toth
Scot H Simpson
Sumit R Majumdar
P304
P356
10.2337/DIACARE.25.12.2244
P407
P577
2002-12-01T00:00:00Z